The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Chemoattractant-Stimulated Rac Activation in Wild-Type and Rac2-Deficient Murine Neutrophils: Preferential Activation of Rac2 and Rac2 Gene Dosage Effect on Neutrophil Functions
Abstract
The hemopoietic-specific Rho family GTPase Rac2 shares 92% amino acid identity with ubiquitously expressed Rac1. Neutrophils from rac2−/− mice have multiple defects, including chemoattractant-stimulated NADPH oxidase activity and chemotaxis, which may result from an overall reduction in cellular Rac or mechanisms that discriminate Rac1 and Rac2. We show that murine neutrophils have similar amounts of Rac1 and Rac2, unlike human neutrophils, which express predominantly Rac2. An affinity precipitation assay for Rac-GTP showed that although FMLP-induced activation of both isoforms in wild-type neutrophils, ≈4-fold more Rac2-GTP was detected than Rac1-GTP. Wild-type and Rac2-deficient neutrophils have similar levels of total Rac1. FMLP-induced Rac1-GTP in rac2−/− neutrophils was ≈3-fold greater than in wild-type cells, which have similar levels of total Rac1, yet FMLP-stimulated F-actin, chemotaxis, and superoxide production are markedly impaired in rac2−/− neutrophils. Heterozygous rac2+/− neutrophils, which had intermediate levels of total and FMLP-induced activated Rac2, exhibited intermediate functional responses to FMLP, suggesting that Rac2 was rate limiting for these functions. Thus, phenotypic defects in FMLP-stimulated Rac2-deficient neutrophils appear to reflect distinct activation and signaling profiles of Rac 1 and Rac2, rather than a reduction in the total cellular level of Rac.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Last, both Rac2 2/2 and Rac2 1/2 mice exhibit decreased neutrophil chemotaxis with decreased F-actin 8 and NADPH oxidase formation in response to fMLF.9”
From Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects (2019) · cites this paper as [8]
Citations
Cites
Identification of two distinct mechanisms of phagocytosis controlled by different Rho GTPases
Caron, E., & Hall, A. (1998) · Science · doi:10.1126/science.282.5394.1717 · Cited by 1,019
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594
Crystal structure of Rac1 in complex with the guanine nucleotide exchange region of Tiam1
Worthylake, D. K., Rossman, K. L., & Sondek, J. (2000) · Nature · doi:10.1038/35047014 · Cited by 355
Molecular basis for Rac2 regulation of phagocyte NADPH oxidase
Diebold, B. A., & Bokoch, G. M. (2001) · Nature Immunology · doi:10.1038/85259 · Cited by 318
Rac and Cdc42 GTPases control hematopoietic stem cell shape, adhesion, migration, and mobilization
Yang, F.-C., Atkinson, S. J., Gu, Y., Borneo, J. B., Roberts, A. W., Zheng, Y., Pennington, J., & Williams, D. A. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.101546898 · Cited by 201
Research works printed but not linked: 67
- 1998, Science, 509
- 2000, EMBO J., 2393
- 2000, Biochem. J., 241
- 1997, Genes Dev., 2295
- 2001, Science, 1299
- 1995, Blood, 1649
- 1991, Nature, 668
- 1991, Science, 1512
- 1996, J. Biol. Chem., 83
- 1997, J. Biol. Chem., 18834
- 1994, Science, 531
- 1999, J. Biol. Chem., 25051
- 1996, Biochemistry, 15683
- 1994, J. Biol. Chem., 30749
- 2001, Nat. Immunol., 211
- 2000, J. Leukocyte Biol., 593
- 1998, Science, 1717
- 1997, J. Exp. Med., 1487
- 2000, J. Cell Biol., 785
- 1989, J. Biol. Chem., 16378
- 1997, J. Biol. Chem., 20384
- 1991, Oncogene, 863
- 1990, Oncogene, 769
- 2001, J. Immunol., 1223
- 2001, Proc. Natl. Acad. Sci. USA, 5614
- 2000, Immunity, 557
- 1999, Immunity, 183
- 2000, Proc. Natl. Acad. Sci. USA, 4654
- 2000, Blood, 1646
- 1999, J. Biol. Chem., 2279
- 1993, Proc. Natl. Acad. Sci. USA, 9832
- 1999, J. Immunol. Methods, 3
- 1997, Blood, 41
- 1999, Trends Pharmacol. Sci., 365
- 2001, J. Biol. Chem., 15929
- 1999, Blood, 1121
- 1999, J. Biol. Chem., 13198
- 1999, J. Biol. Chem., 18055
- 2002, J. Leukocyte Biol., 115
- 1996, J. Biol. Chem., 25204
- 1995, J. Biol. Chem., 19969
- 1993, Mol. Biol. Cell, 261
- 2001, Oncogene, 8057
- 2000, Nature, 682
- 2001, J. Cell Biol., 111
- 1999, Cell, 69
- 1998, J. Biol. Chem., 1782
- 2000, J. Biol. Chem., 32260
- 1998, Oncogene, 1417
- 1998, J. Biol. Chem., 24052
- 2002, J. Biol. Chem., 272
- 1999, Nat. Cell Biol., 98
- 2002, Nat. Cell Biol., 343
- 2002, Cancer Res., 1241
- 2001, Nat. Cell Biol., 368
- 2000, Oncogene, 4582
- 1998, J. Biol. Chem., 21512
- 1995, EMBO J., 5297
- 1996, J. Biol. Chem., 19794
- 1998, J. Biol. Chem., 17991
- 1998, Biochemistry, 7147
- 1995, J. Leukocyte Biol., 108
- 1998, Science, 558
- 1998, Science, 560
- 2001, Oncogene, 6372
- 2002, Cell, 809
- 2000, Science, 1046
Cited by
Granule protein processing and regulated secretion in neutrophils
Sheshachalam, A., Srivastava, N., Mitchell, T., Lacy, P., & Eitzen, G. (2014) · Frontiers in Immunology · doi:10.3389/fimmu.2014.00448 · Cited by 247
Grommes, C., Lee, C. Y. D., Wilkinson, B. L., Jiang, Q., Koenigsknecht-Talboo, J. L., Varnum, B., & Landreth, G. E. (2008) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-007-9090-2 · Cited by 162
Graham, D. B., Robertson, C. M., Bautista, J., Mascarenhas, F., Diacovo, M. J., Montgrain, V., Lam, S. K., Cremasco, V., Dunne, W. M., Faccio, R., et al. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32729 · Cited by 124
Dominant activating RAC2 mutation with lymphopenia, immunodeficiency, and cytoskeletal defects
Hsu, A. P., Donkó, A., Arrington, M. E., Swamydas, M., Fink, D., Das, A., Escobedo, O., Bonagura, V., Szabolcs, P., Steinberg, H. N., et al. (2019) · Blood · doi:10.1182/blood-2018-11-886028 · Cited by 92
Pai, S.-Y., Kim, C., & Williams, D. A. (2010) · Disease Markers · doi:10.1155/2010/380291 · Cited by 85
Ueyama, T., Eto, M., Kami, K., Tatsuno, T., Kobayashi, T., Shirai, Y., Lennartz, M. R., Takeya, R., Sumimoto, H., & Saito, N. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.175.4.2381 · Cited by 50
Metadata
- Authors
- Li, S., Yamauchi, A., Marchal, C. C., Molitoris, J. K., Quilliam, L. A., & Dinauer, M. C.
- Affiliations
- Herman B Wells Center for Pediatric Research and Departments of Pediatrics (Hematology/Oncology), Microbiology/Immunology, and Medical and Molecular Genetics, Biochemistry and Molecular Biology , Indianapolis, IN 46202
- Walther Oncology Center and Walther Cancer Institute , Indianapolis, IN 46202
- James Whitcomb Riley Hospital for Children, Indiana University Medical School , Indianapolis, IN 46202
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2002-11-01
- Volume
- 169
- Issue
- 9
- Pages
- 5043-5051
- ISSN
- 0022-1767
- 1550-6606
- Cited by
- 109
- References
- 5
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review